Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMQRSMD)

Drug Name
Trequinsin Drug Info
Synonyms
trequinsin; Trequinsin [INN]; Trequinsinum [INN-Latin]; Trequinsine [INN-French]; 79855-88-2; UNII-739I2958C1; CHEMBL285913; (2e)-2-(mesitylimino)-9,10-dimethoxy-3-methyl-2,3,6,7-tetrahydro-4h-pyrimido[6,1-a]isoquinolin-4-one; 739I2958C1; Trequinsinum; Trequinsine; C24H27N3O3; 2,3,6,7-Tetrahydro-2-(mesitylimino)-9,10-dimethoxy-3-methyl-4H-pyrimido(6,1-a)isoquinolin-4-one; AC1L1KKE; AC1Q6LSV; Lopac-T-2057; Lopac0_001165; KBioGR_000072; KBioSS_000072; BSPBio_001352; SCHEMBL2777196; SCHEMBL2396911; CHEMBL588593; CHEMBL1411581
Cross-matching ID
PubChem CID
5537
ChEBI ID
CHEBI:93477
CAS Number
CAS 79855-88-2
TTD Drug ID
DMQRSMD
VARIDT Drug ID
DR00496

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Patented Agent(s)
Download the Complete Related Drug List
Drug(s) Targeting Phosphodiesterase 5A (PDE5A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tadalafil DMJZHT1 Benign prostatic hyperplasia GA90 Approved [3]
Udenafil DM1IQRP Erectile dysfunction HA01.1 Approved [4]
Vardenafil DMTBGW8 Cystic fibrosis CA25 Approved [5]
Dipyridamole DMXY30O Atrial fibrillation BC81.3 Approved [6]
Papaverine DMCA9QP Brain ischaemia 8B1Z Approved [7]
Avanafil DM75CXN Erectile dysfunction HA01.1 Approved [8]
Rhucin DM3ADGP Erectile dysfunction HA01.1 Approved [9]
ICARIIN DMOJQGT N. A. N. A. Phase 3 [10]
EXISULIND DMBY56U Colorectal cancer 2B91.Z Phase 3 [11]
PF-489791 DM3C8GQ Chronic obstructive pulmonary disease CA22 Phase 2 [12]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8B (PDE8B)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [13]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [14]
Dexamethasone DMMWZET Acute adrenal insufficiency Approved [15]
Roflumilast DMPGHY8 Asthma CA23 Approved [2]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [16]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [17]
bisphenol A DM2ZLD7 Discovery agent N.A. Investigative [18]
Sulforaphane DMQY3L0 Skin disease EA00-EM0Z Investigative [19]
[3H]cAMP DMZRQU7 Discovery agent N.A. Investigative [20]
⏷ Show the Full List of 9 Drug(s)
Drug(s) Affected By Cystic fibrosis transmembrane conductance regulator (CFTR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ivacaftor DMZC1HS Cystic fibrosis CA25 Approved [21]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [22]
Rhucin DM3ADGP Erectile dysfunction HA01.1 Approved [23]
Quercetin DM3NC4M Obesity 5B81 Approved [24]
Miglustat DM5J64S Niemann-Pick disease type C Approved [25]
Glibenclamide DM8JXPZ Diabetic complication 5A2Y Approved [26]
Milrinone DM8TUPF Congestive heart failure BD10 Approved [23]
Oxidized glutathione DM9EQC0 Breast cancer 2C60-2C65 Approved [27]
Glutathione DMAHMT9 Human immunodeficiency virus infection 1C62 Approved [27]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [28]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By 3',5'-cyclic-AMP phosphodiesterase 4A (PDE4A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tretinoin DM49DUI Acne vulgaris ED80 Approved [29]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [30]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [14]
Folic Acid DMEMBJC Colorectal carcinoma Approved [31]
Roflumilast DMPGHY8 Asthma CA23 Approved [2]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [32]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [33]
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [34]
SNDX-275 DMH7W9X Breast cancer 2C60-2C65 Phase 3 [35]
(+)-JQ1 DM1CZSJ Testicular cancer 2C80 Phase 1 [36]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By 3',5'-cyclic-AMP phosphodiesterase 4B (PDE4B)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tretinoin DM49DUI Acne vulgaris ED80 Approved [37]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [38]
Hydroquinone DM6AVR4 Melasma ED60.1 Approved [39]
Ergotidine DM78IME Osteoarthritis FA00-FA05 Approved [40]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [41]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [42]
Demecolcine DMCZQGK Solid tumour/cancer 2A00-2F9Z Approved [43]
Zoledronate DMIXC7G Adenocarcinoma 2D40 Approved [44]
Niclosamide DMJAGXQ Cestodes infection 1F70-1F76 Approved [45]
Irinotecan DMP6SC2 Adenocarcinoma 2D40 Approved [46]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By 3',5'-cyclic-AMP phosphodiesterase 4C (PDE4C)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methotrexate DM2TEOL Anterior urethra cancer Approved [47]
Quercetin DM3NC4M Obesity 5B81 Approved [48]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [14]
Cupric Sulfate DMP0NFQ Fungal infection 1F29-1F2F Approved [49]
Roflumilast DMPGHY8 Asthma CA23 Approved [2]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [32]
Arsenic DMTL2Y1 N. A. N. A. Approved [50]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [51]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [52]
Vorinostat DMWMPD4 Adult acute monocytic leukemia Approved [53]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By 3',5'-cyclic-AMP phosphodiesterase 4D (PDE4D)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [18]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [29]
Panobinostat DM58WKG Chronic graft versus host disease Approved [35]
Rifampicin DM5DSFZ Non-insulin dependent diabetes 5A11 Approved [54]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [55]
Leflunomide DMR8ONJ Arthritis FA20 Approved [56]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [42]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [57]
Temozolomide DMKECZD Adenocarcinoma 2D40 Approved [58]
Cupric Sulfate DMP0NFQ Fungal infection 1F29-1F2F Approved [49]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B (PDE3B)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tretinoin DM49DUI Acne vulgaris ED80 Approved [29]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [59]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [14]
Roflumilast DMPGHY8 Asthma CA23 Approved [2]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [60]
Triclosan DMZUR4N Malaria 1F40-1F45 Approved [61]
SNDX-275 DMH7W9X Breast cancer 2C60-2C65 Phase 3 [35]
TAK-243 DM4GKV2 Solid tumour/cancer 2A00-2F9Z Phase 1 [62]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [17]
PMID28460551-Compound-2 DM4DOUB N. A. N. A. Patented [63]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By High affinity 3',5'-cyclic-AMP phosphodiesterase 7A (PDE7A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tretinoin DM49DUI Acne vulgaris ED80 Approved [37]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [13]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [14]
Bortezomib DMNO38U Leukemia Approved [64]
Roflumilast DMPGHY8 Asthma CA23 Approved [2]
Arsenic DMTL2Y1 N. A. N. A. Approved [65]
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [34]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [17]
bisphenol A DM2ZLD7 Discovery agent N.A. Investigative [18]
Trichostatin A DM9C8NX Solid tumour/cancer 2A00-2F9Z Investigative [35]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A (PDE3A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Panobinostat DM58WKG Chronic graft versus host disease Approved [35]
Testosterone DM7HUNW Hot flushes GA30 Approved [66]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [66]
Leflunomide DMR8ONJ Arthritis FA20 Approved [56]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [14]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [57]
Dasatinib DMJV2EK Blast phase chronic myelogenous leukemia, BCR-ABL1 positive Approved [67]
Ethinyl Estradiol DMODJ40 Acne vulgaris ED80 Approved [68]
Roflumilast DMPGHY8 Asthma CA23 Approved [2]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [32]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Phosphodiesterase 5A (PDE5A) TTJ0IQB PDE5A_HUMAN Inhibitor [1]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
3',5'-cyclic-AMP phosphodiesterase 4A (PDE4A) OTMUUZLF PDE4A_HUMAN Gene/Protein Processing [2]
3',5'-cyclic-AMP phosphodiesterase 4B (PDE4B) OTOA8WU2 PDE4B_HUMAN Gene/Protein Processing [2]
3',5'-cyclic-AMP phosphodiesterase 4C (PDE4C) OTI8VMHZ PDE4C_HUMAN Gene/Protein Processing [2]
3',5'-cyclic-AMP phosphodiesterase 4D (PDE4D) OT1RWFV0 PDE4D_HUMAN Gene/Protein Processing [2]
cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A (PDE3A) OTKUW1WT PDE3A_HUMAN Gene/Protein Processing [2]
cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B (PDE3B) OT1GI1TE PDE3B_HUMAN Gene/Protein Processing [2]
Cystic fibrosis transmembrane conductance regulator (CFTR) OT6B22QH CFTR_HUMAN Gene/Protein Processing [2]
High affinity 3',5'-cyclic-AMP phosphodiesterase 7A (PDE7A) OTVDV4IT PDE7A_HUMAN Gene/Protein Processing [2]
High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8B (PDE8B) OT4217NK PDE8B_HUMAN Gene/Protein Processing [2]

References

1 Inhibition of cyclic adenosine-3',5'-monophosphate phosphodiesterase from vascular smooth muscle by rolipram analogues. J Med Chem. 1989 Jul;32(7):1450-7.
2 Dynamic activation of cystic fibrosis transmembrane conductance regulator by type 3 and type 4D phosphodiesterase inhibitors. J Pharmacol Exp Ther. 2005 Aug;314(2):846-54. doi: 10.1124/jpet.105.083519. Epub 2005 May 18.
3 Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis. Rheumatology (Oxford). 2009 Jun;48 Suppl 3:iii25-31.
4 Increased expression of the nitric oxide synthase gene and protein in corpus cavernosum by repeated dosing of udenafil in a rat model of chemical d... Asian J Androl. 2009 Jul;11(4):435-42.
5 The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J Am Coll Cardiol. 2002 Dec 4;40(11):2006-12.
6 Anti-platelet therapy: phosphodiesterase inhibitors.Br J Clin Pharmacol.2011 Oct;72(4):634-46.
7 Effects of icariin on cGMP-specific PDE5 and cAMP-specific PDE4 activities. Asian J Androl. 2003 Mar;5(1):15-8.
8 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
9 cGMP-hydrolytic activity and its inhibition by sildenafil in normal and failing human and mouse myocardium. J Pharmacol Exp Ther. 2009 Sep;330(3):884-91.
10 Potent inhibition of human phosphodiesterase-5 by icariin derivatives. J Nat Prod. 2008 Sep;71(9):1513-7.
11 Exisulind induction of apoptosis involves guanosine 3',5'-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin. Cancer Res. 2000 Jul 1;60(13):3338-42.
12 Highlights of the society for medicinesresearch symposium held december 10th 2009 at the national heart and lung institute, London, UK. Drugs of the Future 2010, 35(4): 349-358.
13 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
14 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
15 Identification of mechanisms of action of bisphenol a-induced human preadipocyte differentiation by transcriptional profiling. Obesity (Silver Spring). 2014 Nov;22(11):2333-43.
16 Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
17 Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
18 DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
19 Transcriptome and DNA methylation changes modulated by sulforaphane induce cell cycle arrest, apoptosis, DNA damage, and suppression of proliferation in human liver cancer cells. Food Chem Toxicol. 2020 Feb;136:111047. doi: 10.1016/j.fct.2019.111047. Epub 2019 Dec 12.
20 Molecular cloning and characterization of human PDE8B, a novel thyroid-specific isozyme of 3',5'-cyclic nucleotide phosphodiesterase. Biochem Biophys Res Commun. 1998 Sep 29;250(3):751-6. doi: 10.1006/bbrc.1998.9379.
21 Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med. 2010 Nov 18;363(21):1991-2003. doi: 10.1056/NEJMoa0909825.
22 Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
23 Adenosine receptors and phosphodiesterase inhibitors stimulate Cl- secretion in Calu-3 cells. Am J Respir Cell Mol Biol. 2003 Sep;29(3 Pt 1):410-8. doi: 10.1165/rcmb.2002-0247OC. Epub 2003 Apr 24.
24 Modulation of deltaF508 cystic fibrosis transmembrane regulator trafficking and function with 4-phenylbutyrate and flavonoids. Am J Respir Cell Mol Biol. 2004 Sep;31(3):351-7. doi: 10.1165/rcmb.2002-0086OC. Epub 2004 Jun 10.
25 Proteasome-dependent pharmacological rescue of cystic fibrosis transmembrane conductance regulator revealed by mutation of glycine 622. J Pharmacol Exp Ther. 2008 Apr;325(1):89-99. doi: 10.1124/jpet.107.134502. Epub 2008 Jan 29.
26 Comparative pharmacology of the activity of wild-type and G551D mutated CFTR chloride channel: effect of the benzimidazolone derivative NS004. J Membr Biol. 2003 Jul 15;194(2):109-17. doi: 10.1007/s00232-003-2030-z.
27 Reversible silencing of CFTR chloride channels by glutathionylation. J Gen Physiol. 2005 Feb;125(2):127-41. doi: 10.1085/jgp.200409115. Epub 2005 Jan 18.
28 Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
29 Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
30 Role of NADPH oxidase in arsenic-induced reactive oxygen species formation and cytotoxicity in myeloid leukemia cells. Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4578-83.
31 Folic acid supplementation dysregulates gene expression in lymphoblastoid cells--implications in nutrition. Biochem Biophys Res Commun. 2011 Sep 9;412(4):688-92. doi: 10.1016/j.bbrc.2011.08.027. Epub 2011 Aug 16.
32 Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
33 17-Estradiol Activates HSF1 via MAPK Signaling in ER-Positive Breast Cancer Cells. Cancers (Basel). 2019 Oct 11;11(10):1533. doi: 10.3390/cancers11101533.
34 Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
35 A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
36 Loss of TRIM33 causes resistance to BET bromodomain inhibitors through MYC- and TGF-beta-dependent mechanisms. Proc Natl Acad Sci U S A. 2016 Aug 2;113(31):E4558-66.
37 Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
38 Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation. Blood. 2005 Jul 1;106(1):304-10.
39 Keratinocyte-derived IL-36gama plays a role in hydroquinone-induced chemical leukoderma through inhibition of melanogenesis in human epidermal melanocytes. Arch Toxicol. 2019 Aug;93(8):2307-2320.
40 Histamine up-regulates phosphodiesterase 4 activity and reduces prostaglandin E2-inhibitory effects in human neutrophils. Inflamm Res. 2000 Nov;49(11):600-9. doi: 10.1007/s000110050637.
41 Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
42 Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
43 Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
44 Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
45 Mitochondrial Uncoupling Induces Epigenome Remodeling and Promotes Differentiation in Neuroblastoma. Cancer Res. 2023 Jan 18;83(2):181-194. doi: 10.1158/0008-5472.CAN-22-1029.
46 In vitro and in vivo irinotecan-induced changes in expression profiles of cell cycle and apoptosis-associated genes in acute myeloid leukemia cells. Mol Cancer Ther. 2005 Jun;4(6):885-900.
47 Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
48 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
49 Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
50 Drinking-water arsenic exposure modulates gene expression in human lymphocytes from a U.S. population. Environ Health Perspect. 2008 Apr;116(4):524-31. doi: 10.1289/ehp.10861.
51 Predictive toxicology using systemic biology and liver microfluidic "on chip" approaches: application to acetaminophen injury. Toxicol Appl Pharmacol. 2012 Mar 15;259(3):270-80.
52 Identification of transcriptional biomarkers induced by SERMS in human endometrial cells using multivariate analysis of DNA microarrays. Biomarkers. 2004 Nov-Dec;9(6):447-60.
53 Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
54 Integrated analysis of rifampicin-induced microRNA and gene expression changes in human hepatocytes. Drug Metab Pharmacokinet. 2014;29(4):333-40.
55 Chronic occupational exposure to arsenic induces carcinogenic gene signaling networks and neoplastic transformation in human lung epithelial cells. Toxicol Appl Pharmacol. 2012 Jun 1;261(2):204-16.
56 Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
57 Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
58 Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
59 Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
60 Comparative effects of raloxifene, tamoxifen and estradiol on human osteoblasts in vitro: estrogen receptor dependent or independent pathways of raloxifene. J Steroid Biochem Mol Biol. 2009 Feb;113(3-5):281-9.
61 Transcriptome and DNA methylome dynamics during triclosan-induced cardiomyocyte differentiation toxicity. Stem Cells Int. 2018 Oct 29;2018:8608327.
62 Inhibiting ubiquitination causes an accumulation of SUMOylated newly synthesized nuclear proteins at PML bodies. J Biol Chem. 2019 Oct 18;294(42):15218-15234. doi: 10.1074/jbc.RA119.009147. Epub 2019 Jul 8.
63 Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2019 Nov 15;383:114761. doi: 10.1016/j.taap.2019.114761. Epub 2019 Sep 15.
64 The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide. Exp Hematol. 2011 Jan;39(1):55-65.
65 Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
66 Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
67 Dasatinib reverses cancer-associated fibroblasts (CAFs) from primary lung carcinomas to a phenotype comparable to that of normal fibroblasts. Mol Cancer. 2010 Jun 27;9:168.
68 The genomic response of a human uterine endometrial adenocarcinoma cell line to 17alpha-ethynyl estradiol. Toxicol Sci. 2009 Jan;107(1):40-55.